Aclaris Therapeutics, Inc. Net Fee Amt
Aclaris Therapeutics, Inc. (ACRS) had Net Fee Amt of $20.71 thousand as of 2026-08-04, per its S-3ASR filed 2026-08-06.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-06
- 2026-08-04: Net Fee Amt $20.71K.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-04 | $20.71K S-3ASR · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |